Announcement PDF 23 April 2015 Resonance Health Ltd (ASX:RHT) Appendix 4C – 3rd Quarter Cash Flow Report Resonance Health Limited today released its 3rd quarter Cash Flow Report for the period ending 31 March 2015. Cash at 31 March 2015 was $2.892million representing an increase of $294k for the March quarter. Receipts from customers for the March quarter were higher than the previous quarter as Resonance Health’s prepaid Voucher programme continues to be appreciated by large pharma companies. The analytical services for the prepaid Voucher programme will be delivered over the coming 12 months. The marketing spend in the March quarter, as planned, was $55,000. Company delegates headed to China, France, Portugal and Singapore increasing awareness of HepaFat-Scan® and FerriScan® in the global clinical community. In the coming quarter marketing activities will include attending the following events:  the 2 Liver Forum in Vienna focusing on HepaFat-Scan. The Liver Forum has key industry participants focused on drug development and diagnostics for the treatment of liver disease.  the 50 International Liver Congress (European Association of the Study of the Liver) EASL in Vienna. Our most recent work on HepaFat-Scan will be presented.  the Thalassaemia International Federation (TIF) conference in Athens. TIF is a significant body that advocates the use of FerriScan in thalassaemia patients.  the “Digestive Disease Federation” London conference organised by the British Association of the Study of the Liver. Both FerriScan and HepaFat-Scan will be promoted to hepatology key opinion leaders. This conference combines four other societies including Gastroenterology and Gastrointestinal Surgery which are the key focus areas for Resonance Health. nd th Research and development spend was in line with our planned budget of $66,000 focused on liver fibrosis test. Work on the fibrosis test continues to be a focus for the Company and multiple avenues are being explored. The clinical community is expressing an interest in HepaFat-Scan and the Company is pursuing opportunities to participate in a number of studies both overseas and locally which are anticipated to start in the coming quarter. These studies will generate important data to enhance the acceptance and uptake of HepaFat-Scan and will support incorporation of HepaFat-Scan in clinical guidelines for the management of patients with fatty liver. Resonance Health completed work on its new web site and new logo. The responsive design of the new web site allows easy access to portable devices such as tablets and mobile phones with improved speeds. Investors can subscribe to our ASX market releases http://www.resonancehealth.com/investors/asx-subscribe.html via our new web site. + See chapter 19 for defined terms. Appendix 4C Page 1 For further information please contact: Resonance Health Adrian Bowers Company Secretary T: +61 8 9286 5300 E: adrianb@resonancehealth.com + See chapter 19 for defined terms. Appendix 4C Page 2 Appendix 4C Quarterly report for entities admitted on the basis of commitment Rule 4.7B Appendix 4C Quarterly report for entities admitted on the basis of commitments Introduced 31/3/2000. Amended 30/9/2001 Name of entity Resonance Health Limited Quarter ended (“current quarter”) ABN 96 006 762 492 31 March 2015 Consolidated statement of cash flows Cash flows related to operating activities 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Receipts from customers Payments for (a) staff costs (b) advertising and marketing (c) research and development (d) leased assets (e) other working capital Dividends received Interest and other items of a similar nature received Interest and other costs of finance paid Income taxes (paid)/received Other Receipts/Payments (a) consulting & professional services (b) statutory & compliance (c) grants (d) Due diligence expense Current quarter $A’000 Year to date $A’000 976 (486) (55) (66) (76) 19 1,907 (1,132) (254) (170) (221) 57 (1) (28) (17) 294 (124) 135 (43) 127 Net operating cash flows + See chapter 19 for defined terms. Appendix 4C Page 3 Appendix 4C Quarterly report for entities admitted on the basis of commitment 1.8 1.9 1.10 1.11 1.12 1.13 Current quarter Year to date $A’000 $A’000 Net operating cash flows (carried forward) Cash flows related to investing activities Payment for acquisition of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets Proceeds from disposal of: (a) businesses (item 5) (b) equity investments (c) intellectual property (d) physical non-current assets (e) other non-current assets - (4) - - - - - Loans to other entities Loans repaid by other entities Other (Cash introduced on acquisition of controlled entity) - - Net investing cash flows - (4) 1.14 Total operating and investing cash flows 294 123 1.15 1.16 1.17 1.18 1.19 1.20 Cash flows related to financing activities Proceeds from issues of shares, options, etc. Proceeds from sale of forfeited shares Proceeds from borrowings Repayment of borrowings Dividends paid Other (costs of capital raising) - 650 (19) Net financing cash flows - 631 Net increase (decrease) in cash held 294 754 1.21 1.22 Cash at beginning of quarter/year to date Exchange rate adjustments to item 1.20 2,584 14 2,097 41 1.23 Cash at end of quarter 2,892 2,892 + See chapter 19 for defined terms. Appendix 4C Page 4 Appendix 4C Quarterly report for entities admitted on the basis of commitment Payments to directors of the entity and associates of the directors Payments to related entities of the entity and associates of the related entities Current quarter $A'000 1.24 Aggregate amount of payments to the parties included in item 1.2 1.25 Aggregate amount of loans to the parties included in item 1.11 1.26 Explanation necessary for an understanding of the transactions $38k - $38K – Directors fees Non-cash financing and investing activities 2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows N/A. 2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest N/A Financing facilities available Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2). Amount available $A’000 Amount used $A’000 3.1 Loan facilities - - 3.2 Credit standby arrangements - - + See chapter 19 for defined terms. Appendix 4C Page 5 Appendix 4C Quarterly report for entities admitted on the basis of commitment Reconciliation of cash Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows. 4.1 Cash on hand and at bank 4.2 Deposits at call 4.3 Bank overdraft 4.4 Other (provide details) Current quarter $A’000 Previous quarter $A’000 665 384 - - - - 2,227 2,200 2,892 2,584 - Term deposits Total: cash at end of quarter (item 1.22) Acquisitions and disposals of business entities Acquisitions (Item 1.9(a)) 5.1 Name of entity 5.2 5.4 Place of incorporation or registration Consideration for acquisition or disposal Total net assets 5.5 Nature of business 5.3 Disposals (Item 1.10(a)) N/A N/A Compliance statement 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX. 2 This statement does give a true and fair view of the matters disclosed. Adrian Bowers Company Secretary + See chapter 19 for defined terms. Appendix 4C Page 6